Disc Medicine, Inc. (IRON) stock
IRONNasdaqPharmaceutical PreparationsFiscal year ends December 31
$76.57−0.02 (-0.03%)
Close on Nov 17, 2026Market cap $2.94BP/E –Yield –
Disc Medicine r&d expenses
Research and development expenses are spending on new products and technology.
Disc Medicine's R&D Expenses for the twelve months ending Jun 30, 2026 was $189.40M, up 53.3% year over year. For fiscal 2025 it was $170.64M, up 76.5% from the year before. The highest annual figure on record is $170.64M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $170.64M | +76.5% |
| FY2024 | Dec 31, 2024 | $96.67M | +39.6% |
| FY2023 | Dec 31, 2023 | $69.26M | +107.1% |
| FY2022 | Dec 31, 2022 | $33.44M | +32.8% |
| FY2021 | Dec 31, 2021 | $25.17M | -10.6% |
| FY2020 | Dec 31, 2020 | $28.17M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $46.93M | +1.3% |
| Q1 FY2026 | Mar 31, 2026 | $45.90M | +65.3% |
| Q4 FY2025 | Dec 31, 2025 | $46.22M | +86.4% |
| Q3 FY2025 | Sep 30, 2025 | $50.33M | +103.9% |
| Q2 FY2025 | Jun 30, 2025 | $46.32M | +97.2% |
| Q1 FY2025 | Mar 31, 2025 | $27.76M | +17.1% |
| Q4 FY2024 | Dec 31, 2024 | $24.80M | +9.9% |
| Q3 FY2024 | Sep 30, 2024 | $24.69M | +71.2% |
| Q2 FY2024 | Jun 30, 2024 | $23.49M | +94.1% |
| Q1 FY2024 | Mar 31, 2024 | $23.70M | +17.5% |
| Q4 FY2023 | Dec 31, 2023 | $22.57M | +125.3% |
| Q3 FY2023 | Sep 30, 2023 | $14.42M | +82.8% |
| Q2 FY2023 | Jun 30, 2023 | $12.10M | +56.9% |
| Q1 FY2023 | Mar 31, 2023 | $20.18M | +158.0% |
| Q4 FY2022 | Dec 31, 2022 | $10.02M | -20.7% |
| Q3 FY2022 | Sep 30, 2022 | $7.89M | -41.4% |
| Q2 FY2022 | Jun 30, 2022 | $7.71M | -28.9% |
| Q1 FY2022 | Mar 31, 2022 | $7.82M | -33.6% |
| Q4 FY2021 | Dec 31, 2021 | $12.63M | +64.1% |
| Q3 FY2021 | Sep 30, 2021 | $13.46M | +100.0% |
| Q2 FY2021 | Jun 30, 2021 | $10.84M | +96.1% |
| Q1 FY2021 | Mar 31, 2021 | $11.79M | +43.4% |
| Q4 FY2020 | Dec 31, 2020 | $7.70M | – |
| Q3 FY2020 | Sep 30, 2020 | $6.73M | – |
| Q2 FY2020 | Jun 30, 2020 | $5.53M | – |
| Q1 FY2020 | Mar 31, 2020 | $8.22M | – |
See a number that looks wrong?